Similarly, CD8 was observed to be a strong prognostic factor for risk stratification in breast cancer patients [37], leading to better prognosis, recurrence-free, cancer-specific survival [12,18] and clinical outcome [37,38]. This evidence concerns the gene CD8A and breast carcinoma.